{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:44:44Z","timestamp":1792637084485,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"am","delay-in-days":305,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jpba.2024.116322","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T06:56:09Z","timestamp":1719212169000},"page":"116322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["A rapid LC-MS\/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma"],"prefix":"10.1016","volume":"248","author":[{"given":"Yi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steeve","family":"Rouillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Khemakhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Balakirouchenane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seef","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Rohi","family":"Sanoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Sauvaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Thebault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9borah","family":"Hirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Gana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9o","family":"Froelicher-bournaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116322_bib1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jpba.2024.116322_bib2","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O\u2019Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2024.116322_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jpba.2024.116322_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/cpt.548","article-title":"Can cystic fibrosis patients finally catch a breath with lumacaftor\/ivacaftor?","volume":"101","author":"Schneider","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2024.116322_bib5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MOP.0000000000000627","article-title":"Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis","volume":"30","author":"Burgener","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.jpba.2024.116322_bib6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2024.116322_bib7","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jpba.2024.116322_bib8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jpba.2024.116322_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.jpba.2024.116322_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40272-013-0035-3","article-title":"Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors","volume":"15","author":"Galietta","year":"2013","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.jpba.2024.116322_bib11","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2024.116322_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2016.10.026","article-title":"Development of HPLC and LC-MS\/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO","volume":"1038","author":"Schneider","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2024.116322_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123518","article-title":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","volume":"1213","author":"Ryan","year":"2022","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116322_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/biomedicines11020628","article-title":"Simultaneous quantification of ivacaftor, tezacaftor, and elexacaftor in cystic fibrosis patients\u2019 plasma by a novel LC\u2013MS\/MS method","volume":"11","author":"Pigliasco","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jpba.2024.116322_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FTD.0000000000000829","volume":"43","author":"Vonk","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2024.116322_bib16","doi-asserted-by":"crossref","unstructured":"Venkata M.S., Rao A.L., Carey M.W. Simultaneous Estimation of Ivacaftor and Tezacaftor in Rat Plasma by Liquid Chromatography Coupled with Tandem-mass-spectrometry: Application to Pharmacokinetic Studies. (2021).","DOI":"10.56808\/3027-7922.2526"},{"key":"10.1016\/j.jpba.2024.116322_bib17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple reaction monitoring mass spectrometry for the drug monitoring of ivacaftor, tezacaftor, and elexacaftor treatment response in cystic fibrosis: a high-throughput method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jpba.2024.116322_bib18","first-page":"56084","article-title":"Optimized LC-MS\/MS method for the high-throughput analysis of clinical samples of ivacaftor, its major metabolites, and lumacaftor in biological fluids of cystic fibrosis patients","author":"Schneider","year":"2017","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jpba.2024.116322_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1515\/cclm-2021-0724","article-title":"Isotope dilution LC-MS\/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum","volume":"60","author":"Habler","year":"2022","journal-title":"Clin. Chem. Lab Med."},{"key":"10.1016\/j.jpba.2024.116322_bib20","unstructured":"ICH M10 on Bioanalytical Method Validation. European Medicines Agency (2019) \u3008https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation\u3009 [Accessed November 29, 2019]."},{"key":"10.1016\/j.jpba.2024.116322_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-023-01342-3","article-title":"Lumacaftor\/Ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis: a first step toward personalized therapy","volume":"63","author":"Bouazza","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2024.116322_bib22","unstructured":"PubChem. Elexacaftor. \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/134587348\u3009 [Accessed February 2, 2024]."},{"key":"10.1016\/j.jpba.2024.116322_bib23","unstructured":"Acquity Uplc columns."},{"key":"10.1016\/j.jpba.2024.116322_bib24","first-page":"41","article-title":"Principes de la spectrom\u00e9trie de masse","volume":"2011","author":"Menet","year":"2011","journal-title":"Rev. Francoph. Des. Lab."},{"key":"10.1016\/j.jpba.2024.116322_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00216-011-5706-8","article-title":"Analytical methods for determination of new fluoroquinolones in biological matrices and pharmaceutical formulations by liquid chromatography: a review","volume":"403","author":"Sousa","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2024.116322_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4506","article-title":"Simultaneous quantification of levofloxacin, pefloxacin, ciprofloxacin and moxifloxacin in microvolumes of human plasma using high-performance liquid chromatography with ultraviolet detection","volume":"33","author":"Zheng","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2024.116322_bib27","unstructured":"orkambi-epar-product-information_en.pdf. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orkambi-epar-product-information_en.pdf\u3009 [Accessed January 18, 2024]."},{"key":"10.1016\/j.jpba.2024.116322_bib28","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jcf.2021.01.011","article-title":"Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: rationale and design of the CHEC-SC study","volume":"20","author":"Zemanick","year":"2021","journal-title":"J. Cyst. Fibros."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524003625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524003625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T03:45:39Z","timestamp":1726890339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524003625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"alternative-id":["S0731708524003625"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116322","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rapid LC-MS\/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116322"}}